✦ LIBER ✦

Pharmacokinetics of urinary metabolites of cannabidiol in the dog

✍ Scribed by Emil Samara; Meir Bialer; David J. Harvey

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 422 KB
Volume: 11
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.2510110906

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The pharmacokinetics of cannabidiol (CBD) and six of its urinary metabolites was investigated in dogs. CBD was administered intravenously to three dogs, and urine was collected at specified time intervals over a period of 30h. The apparent terminal half‐life of CBD calculated from the slope of the sigma minus plot was significantly shorter (2h) than the half‐life of CBD calculated from plasma data (8h), and the apparent terminal half‐life of the metabolites was similar to that of the CBD calculated from plasma data, indicating that the elimination of these metabolites was formation rate limited.

The time course of the metabolite excretion could be divided into two phases: the first phase contained mainly monohydroxy metabolites, and the second phase contained mainly metabolites with a carboxylic acid moiety in their side‐chain.

📜 SIMILAR VOLUMES

Pharmacokinetic profile of conjugated ve

Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs

✍ Shimon Barel; Boris Yagen; Meir Bialer 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

The pharmacokinetics and renal excretion of a trichothecene mycotoxin, verrucarol, were studied in six mongrel dogs following IV administration (0.4 mg kg-I). The fraction of verrucarol excreted intact in the urine ranged from 0.9% to 2.7% of the administered dose. The fraction of verrucarol metabo

Pharmacokinetics of tiazofurin in dogs

✍ E. K. Obeng; J. J. Vallner; D. E. Cadwallader; Dr R. L. Tackett 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

The pharmacokinetics of total and free tiazofurin, an antineoplastic agent, was studied in healthy mongrel dogs following intravenous and oral administration of the drug. The free fraction of tiazofurin was obtained from plasma by an ultrafiltration technique using a micropartition system. Total and

Pharmacokinetics of reboxetine enantiome

Pharmacokinetics of reboxetine enantiomers in the dog

✍ E. Frigerio; A. Benecchi; G. Brianceschi; C. Pellizzoni; I. Poggesi; M. Strolin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Reboxetine, (RS)-2-[(RS)-alpha-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate, is a racemic compound and consists of a mixture of the (R,R)- and (S,S)-enantiomers. The pharmacokinetics of reboxetine enantiomers were determined in a crossover study in three male beagle dogs. Each animal receive

Pharmacokinetics of 8-methoxypsoralen in

Pharmacokinetics of 8-methoxypsoralen in the dog

✍ J. G. Monbaliu; F. M. Belpaire; R. A. Braeckman; M. G. Bogaert 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 1 views

The pharmacokinetics of 8-MOP were studied in six dogs following intravenous administration of 2 mg kg-'. In most animals a bi-exponential decline of the plasma level profile was observed. The calculated pharmacokinetic parameters varied considerably between the different dogs. The mean half-lives o

The pharmacokinetics of HI-6 in beagle d

The pharmacokinetics of HI-6 in beagle dogs

✍ Keith J. Simons; Colin J. Briggs 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB 👁 1 views

## Abstract The pharmacokinetics of HI‐6 were studied following intravenous administration to beagle dogs (__n__ = 7). The bioavailability of two different strength intramuscularly administered doses was also determined in the same animals. After a 20 mg kg^−1^ intravenous dose, the mean (±S.D.) in

Pharmacokinetics of pyropheophorbide-a-h

Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog

✍ Payne, John T.; McCaw, Dudley L.; Casteel, Stan W.; Frazier, Donita; Rogers, Kev 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB 👁 2 views

Background and objectiues. Pyropheophorbide-a-hexyl ether (HPPH) is a new compound being investigated for use as a photosensitizer for photodynamic therapy; however, the pharmacokinetics are not known for any of the target species likely to be treated with this drug. The objective of this study was